Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea

Annals of Pharmacotherapy

Volumn 44, Issue 5, 2010, Pages 791-799

  Thayer, Sarah ^a   Arondekar, Bhakti ^b   Harley, Carolyn ^c   Darkow, Theodore E ^d,e  

^a i3 Innovus ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

^c I3 Innovus   (United States)

^d i3 Innovus   (United States)

^e Health Economics and Outcomes Research   (United States)

Author keywords

Adherence; Diabetes mellitus; Fixed dose combination therapy; Glimepiride; Rosiglitazone

Indexed keywords

GLIMEPIRIDE PLUS ROSIGLITAZONE; HEMOGLOBIN A1C; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL;

COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77951585950     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M426     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention, National Center for Health Statistics, Division of Health Interview Statistics. Data from the National Health Interview Survey. www.cdc.gov/diabetes/statistics/prev/national/ figpersons.htm (accessed 2008 Sept 15).
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. www.cdc.gov/diabetes/pubs/factsheets.htm (accessed 2008 Sept 15).
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20. DOI 10.2337/dc08-9017
4. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(suppl 1):S13-S61. DOI 10.2337/dc09-S013
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853 DOI 10.1016/S0140-6736(98)07019-6
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865 DOI 10.1016/S0140-6736(98)07037-8
7. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-431
8. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 DOI 10.1056/NEJMoa0802743
9. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203. DOI 10.2337/dc08-9025
10. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719 DOI 10.1016/j.amjmed.2006.08.033
11. Schectman JM, Bovbjerg VE, Voss JD. Predictors of medication-refill adherence in an indigent rural population. Med Care 2002;40:1294-1300 DOI 10.1097/00005650-200212000-00016
12. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-284 DOI 10.1046/j.1464-5491. 2002.00689.x
13. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847-1853 DOI 10.2337/diacare.20. 12.1847
14. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182-189 DOI 10.1001/jama.285.2.182
15. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-467 DOI 10.1016/S0149-2918(02)85047-0
16. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-2075 DOI 10.1016/j.clinthera.2004.12.018
17. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-574 DOI 10.1002/pds.1230
18. Deyo RA, Cherkin DC, Ciol M. Adapting a clinical comorbidity index for use with ICD -9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
19. Dey J, Blonde L, Guthrie R. Factors influencing patient acceptability of diabetes treatment regimens. Clin Diabetes 2000;18:61.
20. Cheong C, Barner J, Lawson K, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008;30:1893-1907 DOI 10.1016/j.clinthera.2008.10.003
21. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003;26:1408-1412 DOI 10.2337/diacare.26.5.1408
22. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-614 DOI 10.1007/s11606-008-0544-x
23. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003;5:424-431 DOI 10.1046/j.1463-1326.2003.00297.x
24. Duckworth W, Marcelli M, Padden M, et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm 2003;9:256-262
25. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(suppl 1):S13-S61.